AbCellera Biologics Inc.
AbCellera Biologics Inc. is listed today as AbCellera Biologics Inc.: market value, financials and filings are on its company page.
Funding rounds
2 counted as startup funding. Open the number of investors for the round's details.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
As the listed company AbCellera Biologics Inc., its revenue in fiscal 2025 came from these product and service lines: Licensing and royalty revenue $46.92 million (62%), Research fees $27.21 million (36%), Milestone payments $1 million (1%).
Annual report (SEC XBRL) · Dec 2025
AbCellera Biologics Inc. chose not to state its revenue in its newest notice of a funding round (May 2020).
SEC Form D · May 2020
The industry group it chose in its notices: Biotechnology.
SEC Form D · May 2020
Investors#
No investor of AbCellera Biologics Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.
Largest shareholders today
Institutions holding AbCellera Biologics Inc. shares, as of Sep 30, 2026.
- Baker Bros. Advisors LP$482 M10.11%
- Capital World Investors$198 M4.16%
- Two Sigma Investments, LP$171 M3.58%
- TD Waterhouse Canada Inc.$135 M2.82%
- Marshall Wace, LLP$131 M2.74%
- BlackRock, Inc.$83 M1.73%
- ArrowMark Colorado Holdings LLC$70 M1.48%
- Bank Of America Corp /de/$61 M1.28%
- D. E. Shaw & Co., Inc.$53 M1.12%
- Alyeska Investment Group, L.P.$45 M0.94%
- Driehaus Capital Management LLC$41 M0.87%
- Millennium Management LLC$30 M0.62%
- Arrowstreet Capital, Limited Partnership$29 M0.62%
- UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC$26 M0.55%
- Franklin Templeton Inc$22 M0.47%
As of Sep 30, 2026
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Andrew Booth | Executive officer | May 2020 |
| Carl Hansen | Executive officer | May 2020 |
| Stimart Tryn | Executive officer | May 2020 |
| Veronique Lecault | Executive officer | May 2020 |
| Carl Hansen | Director | May 2020 |
| John Hamer | Director | May 2020 |
| Michael Hayden | Director | May 2020 |
| Veronique Lecault | Director | May 2020 |
| Andrew Booth | Director | Aug 2018 |
Went public since 2020. Its SEC number is that of a company listed on a stock exchange.